PSMA PET时代下的PSA持续状态:根治性前列腺切除术后风险因素的再评估
该回顾性多中心研究纳入1188例PSMA-PET分期后接受挽救性放疗的前列腺癌患者,比较PSA持续与生化复发患者的预后。单因素分析中PSA复发者3年BPFS和MFS优于PSA持续者,但多因素分析后BPFS、MFS和OS均无显著差异。提示PSMA-PET高灵敏度可能治疗性地削弱了PSA持续状态的传统不良预后意义。
要点
- PSA持续状态的传统不良预后意义在PSMA-PET时代可能需重新评估。
- 多因素分析中PSA持续与复发患者的BPFS、MFS和OS均无显著差异。
- PSMA-PET检测隐藏病灶的能力可能有助于指导个体化治疗决策。
核心结论
- PSA持续状态传统上被视为不良预后标志,但考虑影像学灵敏度的进步,可能需要重新评估其预后意义。
- 该分析不能确定PSA持续状态是否已不再具有预后价值,但其历史上较差预后可能已被PSMA PET/CT早期局灶检测所治疗性削弱。
研究设计与样本
- 回顾性数据库研究,纳入1222例在5个国家11个中心接受挽救性放疗的PSMA-PET分期前列腺癌患者。
- 排除无PSA持续状态信息的患者后,最终分析1188例。
- 评估PSA持续与复发对总生存(OS)、无转移生存(MFS)和生化无进展生存(BPFS)的影响。
主要发现
- 中位随访时间31.0个月(IQR 20.04-43.6个月)。
- PSMA-PET显示PSA复发患者局部复发发生率更高(43.5% vs. 30.0%,p=0.01),淋巴结失败发生率更低(40.6% vs. 30.5%,p<0.001)。
- 单因素分析中,PSA复发患者3年BPFS(71.5% vs. 63.0%,p=0.033)和MFS(83.0% vs. 78.0%,p=0.049)显著优于PSA持续患者。
- 多因素分析中,BPFS(p=0.738)、MFS(p=0.826)和OS(p=0.730)均无显著差异。
临床怎么用
- PSMA-PET广泛可用后,其检测隐藏病灶的能力可能帮助指导个体化治疗决策。
- PSA持续状态患者的管理可能需要结合PSMA-PET结果重新考量,而非仅依据传统预后判断。
局限性
- 回顾性研究设计。
- 中位随访时间较短(31.0个月)。
- 分析不能 definitively 确定PSA持续状态是否不再具有预后价值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: The association of prostate-specific antigen (PSA) persistence after radical prostatectomy (RP) with inferior prognosis was demonstrated in a systematic review. However, all patients in the included studies lacked a prostate-specific membrane antigen Positron-Emissions-Tomography (PSMA-PET) before salvage radiotherapy (SRT). Since PSMA-PET has markedly improved sensitivity in detecting lymph node and distant metastases, it is unclear whether PSA persistence can be further considered a risk factor in patients or reflects an advanced tumor stage. MATERIALS AND METHODS: We used a retrospective database including 1222 PSMA-PET-staged prostate cancer patients treated with SRT for biochemical recurrence (BR) at 11 centers in five countries. After patients without information on PSA persistence were excluded, 1188 patients remained. The effects of PSA persistence and recurrence on overall survival (OS), metastasis-free survival (MFS), and biochemical progression-free survival (BPFS) were evaluated. RESULTS: The median follow-up time was 31.0 months (IQR range: 20.04-43.6 months). PSMA-PET revealed a higher incidence of local recurrence (43.5% vs. 30.0%, p = 0.01), and lower incidence of nodal failure in patients with PSA recurrence (40.6% vs. 30.5%, p < 0.001). In univariate analysis, patients with PSA recurrence had significantly superior 3-year biochemical progression-free survival (BPFS) (71.5% vs. 63.0%, p = 0.033) and MFS (83.0% vs. 78.0%, p = 0.049) compared to patients with PSA persistence. In the multivariate analysis, no significant differences were observed concerning BPFS (p = 0.738), MFS, (p = 0.826), or OS (p = 0.730). CONCLUSION: PSA persistence, traditionally considered a hallmark of a worse prognosis, may require reevaluation considering advances in imaging sensitivity. While our analysis does not definitively determine whether PSA persistence is no longer prognostic, it remains possible that its historically poorer prognosis and early focal detection via PSMA PET/CT have been therapeutically mitigated. As PSMA-PET becomes more widely available, its ability to detect hidden disease may help guide individualized treatment decisions.
引用
- Scharl S, Thamm R, Zamboglou C, et al. PSA persistence in the PSMA PET era: reassessing a risk factor after radical prostatectomy. Radiother Oncol. 2026. PMID: 42285463. doi:10.1016/j.radonc.2026.111640
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。